St. Louis, Sept. 27, 2005 -- Survival of heart attack and unstable angina patients placed on beta-blocker therapy corresponds to specific variations in their genes, according to a study by researchers ...

Share on Pinterest Experts say a recent study examining a new treatment for a type of heart failure is promising. Sebastian Kahnert/picture alliance via Getty Images Heart failure affects more than 26 ...

Beta3-adrenergic receptors (β3-AR) have emerged as pivotal modulators of cardiac performance, particularly in the context of heart failure. Distinct from the classical β1/β2-adrenergic signalling ...

Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...

The Food and Drug Administration has granted Fast Track designation to APD418 (Arena Pharmaceuticals) for the treatment of decompensated heart failure. The Food and Drug Administration has granted ...

New experimental evidence supports the idea that future therapeutic strategies for treating cardiovascular disease could target sites within the brain. Our recent study demonstrates the existence of ...

November 18, 2009 (Orlando, Florida) — There was no difference in clinical outcomes between 2.5 mg, 5 mg, and 20 mg daily of carvedilol in Japanese heart-failure patients in the Japanese Chronic Heart ...

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...

Experts are warning people against taking the little blue pill celebrities promise will calm nervous jitters in all sorts of stressful situations, from first dates to the Golden Globes. First approved ...